US Patent

US10435692 — Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA

Method of Use · Assigned to Dicerna Pharmaceuticals Inc · Expires 2034-12-26 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods and compositions that use double-stranded RNA to specifically inhibit the enzyme Glycolate Oxidase (HAO1).

USPTO Abstract

This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Drugs covered by this patent

lumasiran-sodium (LUMASIRAN SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2995`	—	lumasiran-sodium

Patent Metadata

Patent number: US10435692
Jurisdiction: US
Classification: Method of Use
Expires: 2034-12-26
Drug substance claim: No
Drug product claim: No
Assignee: Dicerna Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.